Alexion Pharmaceuticals Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Alexion Pharmaceuticals Inc |
Stock Symbol : | NASDAQ: ALXN |
Class Period Start: | 02/10/2014 |
Class Period End: | 11/09/2016 |
Lead Plaintiff motion: | 01/17/2017 |
Date Filed: | 11/17/2016 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Southern District of New York |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the January 17, 2017 lead plaintiff deadline in a class action lawsuit filed against Alexion Pharmaceuticals Inc (NASDAQ: ALXN) (“Alexion” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Alexion Pharmaceuticals Inc securities between February 10, 2014 and November 9, 2016, have until January 17, 2017 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Alexion Pharmaceuticals Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Alexion employed improper sales practices with respect to its product Soliris; that the Company's revenues from Soliris sales were unlikely to be sustainable; and as a result, the Company's public statements were materially false and misleading at all relevant times. On December 12, 2016, Alexion revealed that David Hallal, the Company's CEO and Vikas Sinha, the Company's CFO have both resigned effective immediately. These resignations come amid allegations that Alexion engaged in improper sales practice on its drug Soliris. Following this news, NASDAQ: ALXN dropped 15% during intraday trading on December 12, 2016. If you were negatively impacted by your investment in Alexion Pharmaceuticals Inc securities between February 10, 2014 and November 9, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |